Phase I/II RV-WM-0426 Trial of Lenalidomide and Phase I/II Trial of Oprozomib in Relapsed/Refractory Waldenström Macroglobulinemia


Phase I/II RV-WM-0426 Trial of Lenalidomide and Phase I/II Trial of Oprozomib in Relapsed/Refractory Waldenström Macroglobulinemia
Slides from presentations at ASH 2014
Leleu X et al. Lenalidomide is safe and active in Waldenstrom macroglobulinemia (WM). Proc ASH 2014;Abstract 4478.

Siegel DS et al. Updated results from a multicenter, open-label, dose-escalation phase 1b/2 study of single-agent oprozomib in patients with Waldenstrom macroglobulinemia (WM). Proc ASH 2014;Abstract 1715.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.